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Predictive factors for response to salvage
stereotactic body radiotherapy in
oligorecurrent prostate cancer limited to
lymph nodes: a single institution
experience
Christoph Oehler1*† , Michel Zimmermann1†, Lukas Adam1, Juergen Curschmann2, Marcin Sumila2,
Räto T. Strebel3, Richard Cathomas4, Qiyu Li5, Uwe Schneider2 and Daniel R. Zwahlen1
Abstract
Background: In patients presenting with limited nodal recurrence following radical prostatectomy (RP), stereotactic
body radiotherapy (SBRT) results might improve with a better case selection.
Methods: Single-institution retrospective analysis of patients presenting with 1–3 lymph node (LN) recurrences (N1
or M1a) on 18F-Choline PET/CT. Prior therapy included radical prostatectomy (RP) ± salvage radiotherapy (RT), in absence
of any systemic therapy.
Outcome parameters were biochemical response (BR), time to biochemical recurrence (TBR) and time interval between
SBRT and androgen deprivation therapy start (TADT). Time to event endpoints was analysed using Kaplan-Meier method.
Potential prognostic factors were examined using univariate proportional hazards regression for TADT and logistic
regression for BR. The optimal cut-off point for LN size was calculated using the Contal and O’Quigley method.
Results: 25 patients fulfilling study criteria were treated with SBRT from January 2010 to January 2015 and
retrospectively analysed. Median follow up was 18months and median LN diameter 10.5 mm. SBRT was delivered to a
median dose of 36 Gy in three fractions (range: 30–45 Gy). BR was reached in 52% of cases. Median TBR was 11.9 months
and significantly longer in patients with larger LN (Hazard ratio [HR] = 0.87, P = 0.03). Using 14mm as cut off for LN,
median TBR was 10.8 months for patients with small LN (18 patients), and 21.2 months for patients with large LN (6
patients) (P unadjusted = 0.009; P adjusted = 0.099). ADT was started in 32% of patients after a median follow-up of
18months.
Conclusions: For PCa patients with 1–3 LN recurrence after RP (± salvage RT), SBRT might result in a better biochemical
control when delivered to larger sized (≥ 14mm) LN metastases. This study is hypothesis generating and results should
be tested in a larger prospective trial.
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Background
Prostate cancer (PCa) patients diagnosed with biochem-
ical recurrence and limited metastatic disease are con-
ventionally treated with androgen deprivation therapy
(ADT). Recently, stereotactic body radiation therapy
(SBRT) has emerged as a promising approach for oligo-
metastatic PCa recurrence. This strategy might have the
potential to defer disease progression, thereby lengthen-
ing the time till initiation of hormonal therapy, and thus
improving quality of life.
Results from a recent prospective phase II study
(STOMP trial) suggest that metastasis-directed therapy
(surgery or SBRT) of up to three extracranial metastases
(any N1 or M1) benefited patients by postponing the
start of ADT when compared to surveillance (median
ADT-free survival of 21 months and 13months, respect-
ively) [1]. In a pilot phase I/II study (POPSTAR trial),
SBRT delivered to 1–3 metastatic lesions (bone or LN)
resulted in a 2-year ADT-free survival rate of 48%
among 22 patients who did not have ADT at the time of
SBRT [2]. Results from the promising ORIOLE phase II
trial (52 patients randomized 2: 1 to SBRT or observa-
tion, combined with exhaustive translational research)
are not expected before 2022 [3].
Retrospective series published are quite heterogeneous
regarding the location of treated metastases (including
various amounts of bone, nodal or visceral locations),
the irradiated volume for patients with nodal disease (in-
volved-nodes only, or associated to a prophylactic irradi-
ation of the pelvic lymph drainage), and the initial
radical PCa treatment (mixing radical prostatectomy
(RP) ± radiotherapy (RT) with “RT only” or brachyther-
apy cases) [4].
The aim of this single-institution study was to investi-
gate a homogenous population of exclusively ADT-naïve
prostate cancer patients following RP ± salvage RT, pre-
senting with one to three metachronous LN metastases
on 18F-Choline PET/CT (CholPET/CT) and treated by
SBRT. Endpoints of interest were biochemical response
(BR), time to biochemical recurrence (TBR), and time
interval between SBRT and ADT start (TADT).
Methods
Design and participants
This retrospective study obtained ethical approval. Pa-
tients provided written consent for SBRT treatment and
for the use of their anonymized data for research pur-
poses (ClinicalTrial.gov Identifier NCT03604211).
Inclusion criteria were as follows: histologically proven
diagnosis of PCa; prior treatment with RP and pelvic
lymphadenectomy (± salvage RT limited to the prostatic
bed only), followed by a PSA relapse, defined by two
consecutive rising PSA values > 0.2 μg/l [5]; maximum
one to three N1 or M1a lesions (CholPET/CT positive)
with a controlled primary tumor (CholPET/CT nega-
tive); WHO performance status of 0–1; no prior chemo-
therapy or ADT for PCa (castration-naïve patients).
Exclusion criteria included a primary treatment for
PCa by RT or brachytherapy to achieve a more homoge-
neous patient cohort. PCa patients after RP experience
actually a disturbed lymph drainage, with a high occur-
rence of aberrant LN spread [6], which has not been de-
scribed after primary RT or brachytherapy, as far as we
are aware of. Furthermore, primary RT for high-risk PCa
is often combined with pelvic LN irradiation, which
might lead to delivering non-ablative SBRT for nodal re-
currences in the obturator and iliac basins, to respect
the dose constraints for organs at risk. Similarly, patients
having received salvage RT of the prostatic bed com-
bined with pelvic nodal irradiation were excluded.
Further exclusion criteria were the occurrence of > 3
LN lesions, or bone (M1b) or visceral (M1c) metastases,
or any symptomatic nodal lesion.
LN were considered as positive on CholPET/CT if
either their uptake was markedly increased (higher than
normal liver uptake) or if their uptake was moderately
increased, and their size and shape did not indicate a
clear benign LN. For our study, the reference diameter
was based on the long-axis of positive LN; small-axis di-
ameters were often not mentioned in nuclear medicine
records. Measurements were performed on intravenous
contrast enhanced CT images collected during each
CholPET/CT examination.
PSA doubling-time (PSADT) before SBRT was calcu-
lated using the natural log of 2 divided by the slope of
the linear regression line of the natural log of PSA
against time (months) [7]; results were stratified ac-
cording to three distinct PSADT categories: < 3, 3–6
and > 6 months.
During follow-up after SBRT, patients were reviewed
clinically at approximately 3 to 6 month intervals by
their urologist; PSA testing and imaging frequency was
left up to the discretion of the physician in charge.
For patients experiencing radiological progression after
SBRT, recurrence was considered as in-field, marginal or
out-of-field, if it was located inside, at the border or out-
side the initial planning target volume (PTV).
ADT was started after SBRT for patients with radio-
logical progression of baseline-detected soft-tissue le-
sions using the Response Evaluation Criteria in Solid
Tumours [8], or detection of new bone or soft tissue
metastases, as long as they were not amenable to further
RT. PSA progression only was generally not an indica-
tion to start ADT.
SBRT treatment
All patients were treated with SBRT delivered by Cyber-
Knife®. Patients were immobilized using a customized
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external vacuum-type cast (CIVCO Medical Solutions,
Kalona, IO, USA) prior to their CT planning scan (with-
out IV contrast), acquiring images of 1.5 mm slice
thickness.
Dose and fractionation were dependent on whether
the patient had received previous external beam RT and
normal tissue tolerances within the area to be treated.
The prescribed doses ranged between 30.0 Gy and 45.0
Gy in three fractions, and were defined by the treating
radiation oncologist. The prescribed dose was unrelated
to LN size and increased progressively during the study
period with growing experience. Treatments were de-
signed using Multiplan software (Accuray, version 2.0.5).
The planning target volume (PTV) was generated with
2–4 mm margin around the gross tumor volume (GTV).
SBRT was delivered every other day, using a non-
isocentric treatment technique. Patient movement was
monitored using the CyberKnife® intrafractional image
guidance solution using implanted fiducial markers and
relevant corrections applied.
Endpoints
Endpoints of interest were biochemical response (BR),
time to biochemical recurrence (TBR), and time interval
from SBRT to ADT start (TADT).
PSA reduction in percent was calculated as follows:
100 x [PSA (ug/l) at SBRT- PSA (ug/l) at nadir post-
SBRT/PSA (ug/l) at SBRT].
BR was defined as a reduction in PSA level by more
than 50% of the baseline value, biochemical progression as
a PSA increase ≥25% and ≥ 2μg/l if baseline PSA ≥ 2 μg/l,
or a PSA increase ≥2μg/l if baseline PSA < 2 μg/l [9].
BR was also defined according to Jereczek criteria,
with PSA cut-offs of + 10% (progression), − 10% (minor
response) and − 50% (major response) [10].
TBR was defined as the time interval between SBRT
until second consecutive PSA rise above reference PSA
value. For patients responding to SBRT, the reference
PSA was defined as the PSA nadir after SBRT. For pa-
tients not responding to SBRT, the reference PSA was
the last PSA before SBRT (baseline PSA value).
TADT was defined as the time between SBRT and the
start of palliative ADT or death of any cause.
Toxicity data were not evaluated; follow-up after SBRT
was mostly performed by urologists, and toxicities not
systematically assessed and reported.
Statistical analysis
Descriptive statistics were used to summarize patient
characteristics; results are expressed as median ± inter-
quartile range (IQR). BR was calculated based on the
maximum percentage change in PSA from baseline; it is
reported for each patient using a waterfall plot. Time to
event endpoints were analysed using Kaplan-Meier
method. Time intervals were calculated from SBRT start
to the event of interest. Censoring was at the date of last
clinical follow-up in those not known to be deceased.
Potential prognostic factors including age, last PSA and
PSA doubling-time before SBRT, radiation dose, largest
size and number of LN treated, as well as pathology
results dating back to the initial prostatectomy, salvage
RT after RP or not, were examined using univariate pro-
portional hazards regression for TADT and logistic
regression for BR. The optimal cut-off point for LN size
was calculated using the method proposed by Contal
and O’Quigley [11]; it is based on the log rank test stat-
istic, and allows to identify a cutpoint when the outcome
of interest is measured as time to event. The differences in
survival between the groups were compared by the log-rank
test. Statistical analyses were performed with R version 3.2.3.
Results
Patients
Thirty-eight patients treated with SBRT for oligometa-
static recurrence following primary treatment of local-
ized PCa were identified over a five-year period (January
2010 to January 2015) and entered into study. Thirteen
patients did not meet all our inclusion criteria and had
to be excluded. Three cases did not get RP as primary
treatment [brachytherapy (n = 1) and external beam RT
(n = 2)]. Six cases received ADT before SBRT, and an-
other four were lost to follow-up (international patients
residing outside the country). Twenty-five patients were
included in the analysis.
Initial findings at RP are shown in Table 1. According
to d’Amico classification [12], seven (28%) patients had
intermediate risk disease and 18 (72%) high risk disease.
The median time interval between RP and nodal SBRT
was 35months (range: 8–157). Baseline characteristics at
SBRT are summarized in Table 2. Two thirds (N = 16,
64%) of patients had only one positive LN on CholPET/
CT, with a total of 36 LNs treated for 25 patients, one
third (N = 9, 36%) of patients had 2–3 positive LN on
CholPET/CT. Location and size of involved LN are pro-
vided in Table 2 and (Additional file 1: Table S1).
Median follow-up after SBRT was 18months (IQR: 14–
22). Three patients received a second SBRT treatment:
one patient with infield relapse (obturator LN) and two
cases of out-of-field relapse (obturator LN = > internal
iliac LN; common iliac LN = > para-aortal LN; one
each). Time interval between both SBRT was 8, 13 and
14 months, respectively.
Outcomes
Biochemical response (BR)
Results are provided as a waterfall plot on a per-patient
basis (Fig. 1). BR was observed in 13 patients (52%),
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while five patients (20%) experienced biochemical
progression.
According to the response criteria from Jereczek et
al., 17 patients (68%) experienced a PSA drop by at
least 10%, 13 patients (52%) by more than 50%. On
the other hand, PSA progressed by more than 10% in
six patients (24%).
Time to biochemical recurrence (TBR)
Results from the univariate Cox regression analysis of
the potentially prognostic factors on time between SBRT
and second PSA rise are presented in (Additional file 1:
Table S2). The risk of having a second PSA rise after
SBRT decreased with the size of the largest LN, with a
HR of 0.87 ([95% CI: 0.77–0.99]; P = 0.030). In our study,
a LN size of 14 mm corresponded to the optimal cut-off,
based on the Contal and O’Quigley method [13]. Median
TBR was 10.8 months for patients with small LN, and
21.2 months for patients with large LN (P unadjusted =
0.009; P adjusted = 0.099). Kaplan-Meier curves of TBR
stratified by LN size and number of LN are provided as
Figs. 2 and 3.
Time to ADT
After a median follow-up of 18 months, 68% of patients
remained free of any hormone therapy; ADT was started
in 8/25 cases (32%) during the follow up period.
In a further analysis, we identified T3 stage (HR 9.34
[1.12–77.73] P = 0.039) and extra-prostatic extension at
surgery (HR 10.29 [1.25–84.78] P = 0.030) as risk factors for
a shorter TADT (Additional file 2: Figures S1 and S2). The
influences of the Gleason score and PSA doubling-time on
TADT were statistically not detectable in this small retro-
spective cohort (P = 0.23 and P = 0.47 respectively).
Discussion
To the best of our knowledge, this is one of the largest
retrospective series on LN recurrence treated with
Table 1 Patient and tumor characteristics (n = 25 patients)
Characteristic Value
Initial treatment
RP 10 40%
RP + salvage RT 15 60%
Pre-operative PSA (μg/l)a
median (IQR) 9.1 (5.4–20.4)
mean (range) 12.7 (1.8–40.5)
Gleason score
6 1 4%
7 13 52%
8 7 28%
9 4 16%
T stage
pT2 11 44%
pT3 14 56%
ECE
no 13 52%
yes 12 48%
SVI
no 19 76%
yes 6 24%
SM
negative 13 52%
positive 12 48%
a one data missing (n = 24)
Table 2 Patient and SBRT treatment characteristics (n = 25
patients)
Characteristics Value
Age at SBRT (years)
median (IQR) 68 (62–72)
mean (range) 68 (52–81)
PSA at SBRT (ug/l)
median (IQR) 3.53 (1.48–6.86)
mean (range) 3.49 (1.02–14.54)
PSADT
< 3months 5 20%
3–6 months 12 48%
> 6months 8 32%
Number of lymph nodes at SBRT
1 16 64%
2 7 28%
3 2 8%
LN localisation (n = 36)
N1 33 92%
M1a 3 8%
Largest LN diameter (mm)a
median (IQR) 10.5 (8.5–13.5)
mean (range) 12.8 (5–33)
SBRT data (Gy)
total median dose (range) 36 (30–45)
median dose per fraction (range) 12 (10–15)
SBRT regimen
10 Gy per 3 fractions 2 8%
11 Gy per 3 fractions 1 4%
12 Gy per 3 fractions 11 44%
13 Gy per 3 fractions 7 28%
15 Gy per 3 fractions 4 16%
a one data missing (n = 35)
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ablative SBRT exclusively in ADT-naïve prostate cancer
patients. A biochemical response was observed in 52%
of patients. After a median follow-up of 18 months,
68% patients were free of ADT, and only one of 36
treated LN (2.8%) required a second SBRT for in-field
progression.
Jereczek-Fossa et al. recently reported on a cohort of
94 patients treated with salvage SBRT with a similar
follow-up of 18.5 months [13]; initial treatment of pros-
tate cancer was RP (42%), RP + RT (36%), RT alone
(20%) and brachytherapy (2%), with or without ADT. In
our series, PSA response, stabilization and progression
after SBRT were observed in 68, 8 and 24% of cases,
respectively. Our results replicate the 67, 16 and 18%
reported by the colleagues from Milan, using similar
biochemical response criteria. During the study period,
ADT was started in 32% of our patients and in 36% in
Milan [13]. Interestingly, for those receiving ADT after
SBRT during the study period, treatment could be
deferred by at least 1 year in 63% of our cases but only
in 38% by the Milan group. Potential explanations for a
later ADT start in our institution might include differ-
ences in ADT prescription practices or in tumour
biology (8% M1a LN against 39.5% in Milan), but might
just reflect higher median dose prescriptions (3 × 12 Gy
in our center versus 3 × 8 Gy in Milan), corresponding
to a twice higher biological equivalent dose (BED) with
an α/β = 2 [14, 15] for prostate cancer (BED2 of 252 Gy
versus 120 Gy). The latter BED might not be ablative
for all LN metastases, and would provide a reasonable
explanation for the 10% rate of in-field progression
observed by Jereczek-Fossa et al.
In prostate cancer, conventional imaging has very poor
accuracy for identifying LN metastases. In a meta-
analysis including 24 studies, sensitivity was 42% for CT
and 39% for MRI, specificity 82% for both [16]. Integra-
tion of CholPET/CT into routine evaluation of PCa pa-
tients improved both staging accuracy and RT planning
[17, 18]. The detection rate of CholPET/CT is higher in
cases of high PSA velocity (> 5 μg/l/yr) and short PSA
doubling time (< 2 mo or 3 mo). Detection rate falls to
< 30% for PSA levels < 1 μg/l, but rises > 50% for PSA
levels > 2 μg/l [19]. Kitajima et al. reported a 75% detec-
tion rate for a PSA level between 4 and 10 μg/l [20].
Prostate-specific membrane antigen (PSMA) PET was
not available at the time of our study. PSMA PET out-
performs CholPET/CT for the localization of disease
sites at biochemical recurrence, particularly in small
lymph nodes and at lower PSA levels (< 1 μg/l). [21].
Many PSMA PET positive lesions present actually with-
out an anatomic correlation on CT or MRI, indicating
Fig. 1 Best biochemical response after SBRT
Fig. 2 Time to biochemical recurrence after SBRT according to LN
size (≤ 14 mm vs. > 14 mm)
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that focal treatment can be initiated at an early stage of
metastatic disease [21].
It remains unclear if PSMA PET instead of CholPET/
CT guided salvage treatment would have had a major
impact on our results. PSA levels before SBRT were
quite high in our series (median PSA: 3.53 μg/l); it is
therefore likely that most positive LNs were correctly
identified on CholPET/CT.
This elevated PSA before SBRT rises also the issue of
delayed referral to CholPET/CT, with the advantage to
better select patients with true oligo-recurrent disease
for SBRT, but at the cost of exposing other patients to a
higher risk of delayed treatment for more advanced pro-
gressive disease. This selection bias appears to discrimin-
ate elderly patients, as there are only two octogenerians
in our series (8%). We hypothesize that 80+ year patients
are mostly followed up with PSA and CT scans, and
receive ADT instead of a metastasis-directed therapy at
the time of nodal progression.
We found that salvage SBRT for isolated LN recurrent
PCa provides a twice longer biochemical control (21.8
months vs. 10.8 months) when delivered to patients pre-
senting with larger LN metastases (≥ 14 mm). On the
other hand, the common clinico-pathological risk factors
(T3, Gleason 8–10, PSA doubling time < 3months)
didn’t lead to a shorter TBR (Additional file 1: Table S2).
At first glance, such results appear counterintuitive, as
one would expect larger LN to reflect a higher tumor
burden and a more advanced stage of disease, leading to
a shorter TBR. These patients with 1–3 LN macrometas-
tases, despite high-risk features at the time of RP, exhibit
a phenotype of slow lymphatic spreading, with only a
few LN metastases growing up over time without devel-
oping multiple new lesions (true oligometastatic disease).
Given the retrospective nature of the study design, we
hypothesize that our data result from a selection bias,
selecting tumors that didn’t develop yet multiple mecha-
nisms of immune evasion. Identifying the underlying gene
expression pattern in such patients would allow in the
future for a better selection of candidates to metastasis-di-
rected SBRT, and for an earlier start of treatment
(PSA < 1.0 μg/l and LN size < 1 cm). MicroRNA pro-
filing shows substantial potential to be used as prog-
nostic biomarker for individuals with oligometastatic
prostate cancer [22–25].
The main strength of this study relies on quite restrict-
ive inclusion criteria, leading to a series of 25 consecu-
tive patients with a limited nodal recurrence (1–3 LN)
after RP, in the absence of any prior or concomitant
ADT. Regarding treatment, SBRT was always delivered
at ablative doses (median dose: 36 Gy/ 3 fractions [range:
30–45 Gy]).
Our series has several limitations. The number of in-
cluded patients was low, limiting the validity of subgroup
analysis; observed results could have occurred merely by
chance. Imaging and PSA levels during follow-up after
SBRT were not obtained at predefined time points. We
didn’t stage our patients with PSMA-PET, which has
been shown in multiple studies to be superior to Chol-
PET/CT imaging in the setting of biochemical relapse
[26]. Further drawbacks include the lack of confirmatory
biopsy for PET-positive LN, the absence of radiological
response assessment after SBRT, and the lack of a con-
trol group. Time to ADT might also have been sub-
scriber biased due to the lack of predefined prescription
criteria. Finally, our results might not apply to patients
with nodal metastases occurring with concomitant local
recurrence (prostate bed) and/or distant (bone) metasta-
ses, nor to patients with castrate-resistant prostate can-
cer presenting with oligo-progressive disease.
Last, for patients experiencing isolated metastatic LN
recurrence after primary treatment, there are currently
no consensus guidelines on which strategy to follow.
Besides treating only positive LN with SBRT, which
could be considered in one sense as “just targeting the
tip of the iceberg”, more comprehensive strategies might
be applied as well, like salvage radiation of the whole
pelvic lymph node basin combined with a simultaneous
integrated boost (SIB) to PET-positive LNs, using either
CholPET/CT [27] or PSMA PET/CT guided RT [28].
Extended salvage lymph node dissection (sLND) might
be a valid option for selected patients, but remains tech-
nically challenging: sLND alone is usually not associated
with a durable biochemical response; 50–80% of patients
will receive some kind of adjuvant treatment right after
sLND (ADT or RT) regardless post-operative PSA levels
[29]. In an interesting retrospective analysis of 93 pa-
tients, adjuvant RT after sLND was shown to improve
significantly the 5 year- relapse-free survival from 15.4%
Fig. 3 Time to biochemical recurrence after SBRT according to LN
number (1 vs. 2–3)
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in the surgery only group to 34.3% in the group with
additional RT (P = 0.0122) [30]. Prospective random-
ized trials are warranted to confirm these encouraging
results.
Conclusions
The present work underlines the possible role of ablative
SBRT in the management of patients affected by LN
oligo-recurrent disease. In ADT-naïve prostate cancer
patients with 1–3 LN metastases after definitive RP,
SBRT can offer a good control of asymptomatic disease.
After a median follow-up of 18 months, 68% of patients
remained free from ADT. Our study is the first to date
attempting to define an optimal LN size threshold prior
to SBRT. Additional studies are required before the
results should be used in usual clinical settings.
Additional files
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